Segment Reporting (Details) - USD ($) |
9 Months Ended | |
|---|---|---|
Mar. 31, 2026 |
Mar. 31, 2025 |
|
| Segment Reporting [Abstract] | ||
| Clinical studies | $ 6,602,000 | $ 4,097,000 |
| Clinical teams | 3,255,000 | 2,968,000 |
| Chemistry, manufacturing and controls | 142,000 | 726,000 |
| Other research and development expenses | 384,000 | 251,000 |
| General and administrative expenses | 6,377,000 | 6,189,000 |
| Amortization of intangible assets | 172,000 | 172,000 |
| Other income, net | (505,000) | (350,000) |
| Net loss | $ (16,427,000) | $ (14,053,000) |
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of revenue and income classified as other. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- References No definition available.
|